ClinicalTrials.gg
RecruitingNCT07382596Updated Nov 9, 2026

Cervical Plexus Hydrodissection With D5W Versus NS for Treatment-Resistant PTSD

A Phase 4 interventional study of Dextrose 5% in water bilateral injection and Normal saline bilateral injection in PTSD, sponsored by Dr. Dean Reeves Clinic. Recruiting at 4 sites in United States. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Dr. Dean Reeves Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 9, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
867th of 1,491
50 · median 65
Started
2026
with 96 others
Phase 4
90 of 1,664
9 open now
Primary completion
2030-03
later than 363 of 402 live
Registered
1,591st of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 867th largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 97 that started in 2026, is one of 90 in phase 4, reaches primary completion later than 363 of the 402 other live ones, and was the 1,591st registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 19 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with an injection control of normal saline (NS)

Read the detailed description

PTSD is a well-recognized debilitating mental health condition associated with previous trauma exposure. It is part of the DSM-5 Trauma and Stressor related disorders category. Treatments for PTSD normally involve a multi-disciplinary approach. First-line treatments include psychotherapy and serotonergic reuptake inhibitors. Many patients fail pharmacotherapy and psychotherapy. Unilateral stellate ganglion block performed favorably for treatment of PTSD in a recent RCT, based upon an expectation that the cervical sympathetic system is neuropathically upregulated in PTSD. However, inclusion of lidocaine requires the presence of an emergency response team due to the potential for inadvertent intravascular injection with generalized seizures or hypotension, and inadvertent laryngeal or phrenic nerve block. Perineural injection of peripheral nerves, plexi, or sympathetic ganglia with dextrose 5% in water (D5W), has performed well empirically in the treatment of post-traumatic stress disorder. No lidocaine is utilized, which allows for avoidance of lidocaine toxicity risk, or any risk of nerve block. Because of that, bilateral procedures are feasible, and these procedures can be performed in any outpatient office with ultrasound availability, as emergency team backup is not necessary, making the procedure readily accessible. A cumulative benefit has been observed, as well. The effects of BHDCP with D5W as a stand-alone treatment for PTSD is under evaluated in a randomized trial compared treatment with D5W versus delayed treatment with early results promising. This study is designed as the next step in study quality through use of an injection control. The primary outcome is the short term and long-term effect of BHDCP with D5W versus NS on the Post Traumatic Stress Disorder Check List for Civilians (PCL-C), The primary hypotheses are tha cervical plexus hydrodissection with D5W will outperform NS for the primary measure, and that the PCL_C improvement will be equal to or greater than 15.3 (1.5 times the MCID of 10.2.). A study size of 100 participants is planned, based on power analysis.

03

Conditions studied

  • PTSD

Keywords

  • Dextrose
  • Hydrodissection
  • Cervical Plexus
04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • Not involved in another study of PTSD treatment
  • Reliable transportation
  • Comfortable with computers
  • Tried 2 or more medications for treatment of PTSD symptoms
  • Tried 2 or more non-medication treatments for PTSD symptom
  • No known life-threatening illness
  • Not taking daily narcotics
  • Not having 3 or more alcoholic drinks on an average day
  • No active suicidal plans
  • No major surgery plans
  • No major life stress that might interfere with completing study
  • Symptoms for more than 1 year
  • Not planning to move for next 18 months.
  • Living within an hour of Portland, OR, Madison, WI, or Lexington, KY
  • Wiling to provide 2 email and 2 phone contact methods
  • Willing to answer questions on multiple occasions over the course of a year.
  • Willing to be assigned to 3 months of usual care treatment
  • No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder.
  • No severe needle phobia
  • Chronic pain ≤ 5/10
  • PCL-C score ≥ 50

Exclusion Criteria:

-

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    D5W cervical plexus hydrodissection

    10 ml D5W cervical plexus hydrodissection bilaterally at 0, 2, 4, and 8 weeks, and then by request from 13-52 weeks

    Drug: Dextrose 5% in water bilateral injection

  • Active comparator
    Normal saline cervical plexus hydrodissection

    10 mL normal saline cervical plexus hydrodissection bilaterally at 0, 2, 4, and 8 weeks, and then D5W by request from 13-52 weeks

    Drug: Normal saline bilateral injection

Interventions

  • DrugGlucoseStudies of GlucoseGlucose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection under the investing fascia of the sternocleidomastoid muscle

  • DrugNormal saline bilateral injection

    Injection under the investing fascia of the sternocleidomastoid muscle

06

What researchers measure

Primary outcomes

  1. Post traumatic checklist for civilians

    Minimum 17 Maximum 85 Higher scores mean worse outcome

    Time frame: 3 months

Secondary outcomes

  1. Hospital anxiety and depression scale

    Minimum 0 Maximum 42 Higher scores mean worse outcome

    Time frame: 3 months

  2. EuroQol Visual Analog Scale (0-100 overall quality of life)

    Minimum 0 Maximum 100 Higher scores mean better outcome

    Time frame: 3 months

07

Study locations

3 of 4 sites recruiting
  • Wellward Medical
    Lexington, Kentucky 40509, United States
    Not yet recruiting
  • NW Regen
    Portland, Oregon 97210, United States
    Recruiting
  • Paul Johnson, MD.
    Portland, Oregon 97210, United States
    Recruiting
  • Medical Procedures of Wisconsin
    Madison, Wisconsin 53709, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data are available from the first author upon request in writing and with a detailed use plan.

Time frame: 10 years

Access criteria: Request in writing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2030, 45 months after the start.

Of 30 non-industry phase 4 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 71. This study's planned 45 months is below that.

Counting every sponsor, half of 31 studies reached it within 52 months; a quarter within 36 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2026
First posted
Feb 3, 2026
StartActual
May 16, 2026
Primary completionEst.
Mar 1, 2030
CompletionEst.
Apr 1, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Wellward Medical is now Not yet recruiting
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Wellward Medical is now Not yet recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07382596
Lead sponsor
Dr. Dean Reeves Clinic
Responsible party
Dr. Dean Reeves (Principal Investigator, Dr. Dean Reeves Clinic) — Principal investigator
First posted
Feb 3, 2026
Start date
May 16, 2026
Primary completion
Mar 1, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Kenneth D Reeves, MD
Contact
DeanReevesmd@gmail.com
9133621600
Clare R Solso, RN
Contact
cereeves2002@hotmail.com
405 819 7777
Kenneth D Reeves, M.D.
principal investigator · Dr. Dean Reeves Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucose

Start the discussion